Scientists have developed a modified version of an aminoglycoside, the most commonly used class of antibiotics worldwide, that may eliminate the risk of hearing loss.
Treatment with aminoglycosides is often a lifesaving necessity. However, an estimated 20-60% of all patients who receive these antibiotics suffer partial or complete hearing loss.
Antibiotics
Antibiotics are among the most used and abused medications. This article explains some general features about antibiotics.
Advertisement
Researchers at the Stanford University School of Medicine have conducted a study where the new version of antibiotic worked effectively in mice without the risk of causing deafness.
It took the scientists 4 years of research to produce 5 grams of the newly patented antibiotic, N1MS, which is derived from sisomicin, a type of aminoglycoside.
![Drug Resistance - Antibiotic Resistance]( "Drug Resistance - Antibiotic Resistance")
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.
The study presents a promising new approach to generating a new class of novel, nontoxic antibiotics.
Because aminoglycosides cause deafness by killing these nonregenerating hair cells, Anthony Ricci, PhD, postulated, why not simply make the drug molecules unable to enter the cells' channels.
"The goal was to keep the antibacterial properties of the drug intact while preventing it from entering the inner-ear cell's ion channels," Ricci said. He and his fellow researchers used data from structural biologists at Stanford who better understood how the antibiotics fought off infection.
Ricci targeted sites on the drug molecule that were not involved in the antimicrobial activity that killed off infection. This allowed them to reduce toxicity to the ear while retaining antimicrobial action.
The study was published online in the Journal of Clinical Investigation.
Source: Medindia
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.
Advertisement
The study presents a promising new approach to generating a new class of novel, nontoxic antibiotics.
Because aminoglycosides cause deafness by killing these nonregenerating hair cells, Anthony Ricci, PhD, postulated, why not simply make the drug molecules unable to enter the cells' channels.
"The goal was to keep the antibacterial properties of the drug intact while preventing it from entering the inner-ear cell's ion channels," Ricci said. He and his fellow researchers used data from structural biologists at Stanford who better understood how the antibiotics fought off infection.
Ricci targeted sites on the drug molecule that were not involved in the antimicrobial activity that killed off infection. This allowed them to reduce toxicity to the ear while retaining antimicrobial action.
The study was published online in the Journal of Clinical Investigation.
Source: Medindia
Natural Antibiotics to Fight Bacterial Infections
Fighting infections the natural way and preventing them is always more effective than consuming medicines and antibiotics to treat them.
Advertisement
 Antibiotic Resistant Bacteria on the Rise Due to Reckless Use of AntibioticsIn a shocking study, it has been estimated that about two million Indians are likely to die every year by 2050, by a British economist earlier this month. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.